First Peer-Reviewed Study Documents Magnetism Following COVID-19 Injection

A groundbreaking study, recently published on June 1, 2025, in Proteomics Clinical Applications, explores the rare—and once denounced in connection with the mRNA COVID-19 jabs—phenomenon called “iatrogenic magnetism.” The study documents cases where metallic objects, like utensils or coins, reportedly clung to patients’ bodies for months after vaccination. Although the ramifications of these occurrences are indeed broad and frightening, the study authors raise concerns about potential health risks associated with medical procedures, such as MRI scans, which utilize powerful magnets.

The study, a Case Series titled “Clinical Manifestations of Iatrogenic Magnetism in Subjects After Receiving COVID-19 Injectables: Case Report Series,” investigated iatrogenic magnetism in six Case Subjects and observed that small ferromagnetic items, such as spoons, coins, or magnets, stuck to areas like the forehead, temples, chest, or shoulders of these patients. The effect was not just anecdotal—scientists physically verified it, often documenting the phenomenon with photographs to confirm its occurrence.

Interestingly, the magnetic outcome didn’t appear immediately after receipt of the experimental mRNA COVID-19 jabs but developed over time, typically between 1- and 20-months post-injection. This delayed onset suggests that the magnetism isn’t caused by leftover vaccine material at the injection site. Instead, it may result from systemic changes in the body, possibly linked to the genetic expression of vaccine components, such as mRNA or DNA, which they note could spread throughout the body and trigger this unusual effect. With transhumanism on the horizon, this outcome is nothing short of terrifying.

As noted above, the researchers, who are from Finland, suggest that the magnetism may be related to the mRNA or DNA components of the vaccines, which instruct cells to produce spike proteins. They note that these spike proteins, or related peptides, could have ferromagnetic properties, indicating they attract metal. Likewise, another theory suggests that the spike protein may disrupt the body’s iron regulation because it shares some similarities with hepcidin, a protein that regulates iron metabolism. This disruption could lead to iron buildup in tissues, such as the brain, potentially causing the magnetic effect.

As expected, the study reported that these concerning cases of magnetism were more commonly linked to specific Pfizer vaccine batches, particularly those with lot numbers beginning with the letter “F.” While Moderna vaccines were also associated with some cases, the connection was less frequent, suggesting possible differences in vaccine formulations or manufacturing processes that might contribute to the phenomenon. As noted by Nicolas Hulscher, MPH, Epidemiologist and Foundation Administrator at the McCullough Foundation, there is no mention of this phenomenon in Pfizer’s internal documents or in VAERS, despite numerous anecdotal reports.

Given the recklessness and disregard for safety related to the mRNA injections, this serious omission is not surprising. Hulscher, who also referenced a 2021 study noting that “a strong magnetic field is generated in the human body that has no casual relationship to previous COVID-19 vaccination,” broke down The Cases in the recent study as follows:

Case 1:
A 53-year-old male with no prior history of magnetism developed magnetic adhesion of a 25g object to both temples approximately 15 months after receiving two Pfizer injections (lots EY3014 and FE3065). He experienced chest pain, arrhythmia, full-body tremors, cognitive impairment, and other systemic symptoms.

Case 2:
A previously healthy 39-year-old female developed magnetism in her forehead and right shoulder—at the injection site—around one month after receiving a single Pfizer dose (lot FL4574). A 42g metal object adhered to her forehead, causing pain; symptoms lessened with alcohol and intensified during grounding.

Case 3:
A 28-year-old female developed magnetism approximately 20 months after receiving two Pfizer injections (lots FE2296 and FH0161). A 45g metal object adhered to her forehead, temple, and chest, but the magnetism faded over time, possibly due to self-initiated NAD⁺ therapy (500 mg/day).

Case 4:
A 28-year-old male reported magnetism of a 42g metal object to his left temple and ribcage around 20 months post-injection with both Pfizer (lot FH9951) and Moderna (lot 3004494). Cognitive symptoms and visual disturbances during MRI resolved with NAD⁺ but relapsed after discontinuation.

Case 5:
A 32-year-old previously healthy male, the spouse of Case 2, developed magnetism two months after receiving the Pfizer vaccine (lot FL4574). A 70g metal object adhered to his forehead, chest, and shoulder opposite the injection site, with no improvement from food or medication.

Case 6:
A 36-year-old female developed strong magnetism (~25g object adherence to her sternum) one month after receiving the Pfizer and Moderna vaccines (lots 1F1012A and 3006274). Her unvaccinated 10-year-old son also developed similar chest-localized magnetism, raising the possibility of vaccine-related shedding.

In addition to magnetism, some patients reported severe health issues, including neurological problems like tremors or cognitive decline and cardiovascular symptoms like irregular heart rhythms. Interestingly, as noted above, in at least two cases, taking 500 mg of oral NAD⁺ supplements daily appeared to reduce or even eliminate the magnetism and related symptoms, suggesting that the effect might be reversible. However, further research is needed to understand why this treatment was effective and whether it could benefit others. Stating that the phenomenon of magnetism is “real and not a placebo effect” in some COVID-19 patients, the study authors concluded:

“This observation raises justifiable questions about the content of COVID-19 injectables and the complete lack of mandatory quality control by regulatory bodies. We urgently need answers to our questions through the transparency program initiated by the newly elected HHS secretary Robert Kennedy Jr. Our preliminary findings should be corroborated by additional studies in a larger cohort.”